{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05994937",
            "orgStudyIdInfo": {
                "id": "23-00755"
            },
            "organization": {
                "fullName": "NYU Langone Health",
                "class": "OTHER"
            },
            "briefTitle": "Cleaner Air for Lower Cardiometabolic Risk",
            "officialTitle": "Glycemic and Cardiometabolic Biomarker Improvements Associated With Reduction in Air Pollution Exposure",
            "therapeuticArea": [
                "Endocrinology"
            ],
            "study": "cleaner-air-for-lower-cardiometabolic-risk"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-02",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-12-26",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-06-30",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-07-30",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-08-09",
            "studyFirstSubmitQcDate": "2023-08-09",
            "studyFirstPostDateStruct": {
                "date": "2023-08-16",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-02-21",
            "lastUpdatePostDateStruct": {
                "date": "2024-02-23",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "NYU Langone Health",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "Doris Duke Charitable Foundation",
                    "class": "OTHER"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": false,
            "isFdaRegulatedDevice": true,
            "isUsExport": true
        },
        "descriptionModule": {
            "briefSummary": "The purpose of this interventional sham-controlled pilot study is to study the effects of using portable air cleaners (PACs) in outpatient adults with prediabetes. The primary aims are to determine the effect PAC's have on glycemic variability and the concentrations of circulating biomarkers of inflammation."
        },
        "conditionsModule": {
            "conditions": [
                "PreDiabetes"
            ],
            "keywords": [
                "Air pollution",
                "prediabetes",
                "inflammation",
                "cardiovascular disease prevention",
                "blood sugar"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "NA"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "PREVENTION",
                "maskingInfo": {
                    "masking": "DOUBLE",
                    "whoMasked": [
                        "PARTICIPANT",
                        "CARE_PROVIDER"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 142,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Active Portable Air Cleaner (PAC) Filtration",
                    "type": "EXPERIMENTAL",
                    "description": "High Efficiency Particulate Air (HEPA) filter will be left intact in the PAC for 4 weeks.",
                    "interventionNames": [
                        "Device: PAC with HEPA filter intact"
                    ]
                },
                {
                    "label": "Sham Portable Air Cleaner (PAC) Filtration",
                    "type": "SHAM_COMPARATOR",
                    "description": "High Efficiency Particulate Air (HEPA) filter will be removed from the PAC for 4 weeks.",
                    "interventionNames": [
                        "Device: PAC with HEPA filter removed"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DEVICE",
                    "name": "PAC with HEPA filter intact",
                    "description": "A commercially available PAC with a true HEPA filter will be used. Unit will be placed in the bedroom and used continuously (24 hours/day) for a total of 4 weeks.",
                    "armGroupLabels": [
                        "Active Portable Air Cleaner (PAC) Filtration"
                    ]
                },
                {
                    "type": "DEVICE",
                    "name": "PAC with HEPA filter removed",
                    "description": "Uses the same model as the experimental PAC that is identical in appearance and sound with the HEPA filter removed . Unit will be placed in the bedroom and used continuously (24 hours/day) for a total of 4 weeks.",
                    "armGroupLabels": [
                        "Sham Portable Air Cleaner (PAC) Filtration"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Percent Change in A Continuous Glucose Monitor (CGM) Coefficient of Variation (CV)",
                    "description": "A CGM will be placed at baseline to continuously measure glucose, which will then be used to assess glycemic variability at the end of 4 weeks post-intervention. This outcome will be measured using the following equation: ((\\[post-intervention\\]-\\[pre-intervention\\]))/(\\[pre-intervention\\])\\*100%",
                    "timeFrame": "Baseline, Week 4"
                },
                {
                    "measure": "Percent Change of C-reactive Protein (CRP) Biomarkers",
                    "description": "This outcome will be measured using the following equation: ((\\[post-intervention\\]-\\[pre-intervention\\]))/(\\[pre-intervention\\])\\*100%",
                    "timeFrame": "Baseline, Week 4"
                },
                {
                    "measure": "Percent Change in Concentration of Interleukin-6 (IL-6) Biomarkers",
                    "description": "This outcome will be measured using the following equation: ((\\[post-intervention\\]-\\[pre-intervention\\]))/(\\[pre-intervention\\])\\*100%",
                    "timeFrame": "Baseline, Week 4"
                },
                {
                    "measure": "Percent Change in Concentration of Tumor Necrosis Factor-alpha (TNF\u03b1) Biomarkers",
                    "description": "This outcome will be measured using the following equation: ((\\[post-intervention\\]-\\[pre-intervention\\]))/(\\[pre-intervention\\])\\*100%",
                    "timeFrame": "Baseline, Week 4"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Participant is \u226518 years old\n* Participant and members of household are reported to be non-smokers (defined as no household members are currently known to smoke cigarettes or use other tobacco products including e-cigarettes)\n* Participant is to understand/speak English or Spanish\n* Participant can understand study procedures and give informed consent\n* Participant has prediabetes, defined as the absence of diabetes and any of the following: fasting plasma glucose 100-125 mg/dL, 2 hour plasma glucose of 140-199 mg/dL after 75 g oral glucose tolerance test, or A1c 5.7- 6.4%.\n* Able to wear CGM for 2 two-week periods\n* Able to participate in telephone or video conference for home equipment setup if needed\n* Able to visit clinic for blood draws before and after the study period\n* Do not intend to sleep anywhere outside of primary bedroom for more than 48 consecutive hours or a total of 7 days during the study period.\n* Ability to lift, or access to assistance with lifting, 20 lb to set up air filter appliance in bedroom.\n* Have not undergone major dietary change (such as change from usual diet to intermittent fasting or caloric restriction) in the past 2 weeks, and do not intend to during the study period\n\nExclusion Criteria:\n\n* Participants who have diagnosed diabetes, or take antihyperglycemic medications\n* Participants with known atherosclerotic disease: coronary artery disease, peripheral artery disease or history of cerebrovascular disease (stroke or Transient Ischemic Attack (TIA), carotid stenosis)\n* Participants with known systemic inflammatory conditions (including but not limited to: inflammatory arthritis, vasculitides, inflammatory bowel diseases, cancer within past 5 years, Hashimoto's thyroiditis)\n* Participants currently taking any anti-inflammatory medications or medications that target inflammatory cytokines\n* Pregnancy: because blood glucose problems during pregnancy require intensive monitoring and lifestyle changes to protect the mother and fetus\n* Participants with known or suspected Covid-19 in the prior 30 days\n* Participants with post-covid sequelae (a.k.a \"Long covid\")\n* Participants who are already utilizing HEPA filtration (PAC or within HVAC) in bedrooms",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "85 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Sharine Wittkopp",
                    "role": "CONTACT",
                    "phone": "646-501-8121",
                    "email": "Sharine.Wittkopp@nyulangone.org"
                },
                {
                    "name": "Jonathan Newman",
                    "role": "CONTACT",
                    "phone": "212-263-9393",
                    "email": "Jonathan.Newman@nyulangone.org"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Jonathan Newman",
                    "affiliation": "NYU Langone Health",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "NYU Langone Medical Center",
                    "status": "RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10016",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "YES",
            "description": "The de-identified participant data from the final research dataset used in the published manuscript will be shared upon reasonable request beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research provided the investigator who proposes to use the data executes a data use agreement with NYU Langone Health. Requests may be directed to: Sharine.Wittkopp@nyulangone.org. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research",
            "infoTypes": [
                "STUDY_PROTOCOL",
                "SAP"
            ],
            "timeFrame": "Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.",
            "accessCriteria": "The investigator who proposed to use the data will be provided access upon reasonable request. Requests should be directed to Sharine.Wittkopp@nyulangone.org. To gain access, data requestors will need to sign a data access agreement."
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000011236",
                    "term": "Prediabetic State"
                },
                {
                    "id": "D000018149",
                    "term": "Glucose Intolerance"
                }
            ],
            "ancestors": [
                {
                    "id": "D000003920",
                    "term": "Diabetes Mellitus"
                },
                {
                    "id": "D000044882",
                    "term": "Glucose Metabolism Disorders"
                },
                {
                    "id": "D000008659",
                    "term": "Metabolic Diseases"
                },
                {
                    "id": "D000004700",
                    "term": "Endocrine System Diseases"
                },
                {
                    "id": "D000006943",
                    "term": "Hyperglycemia"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M10293",
                    "name": "Inflammation",
                    "relevance": "LOW"
                },
                {
                    "id": "M14117",
                    "name": "Prediabetic State",
                    "asFound": "Prediabetes",
                    "relevance": "HIGH"
                },
                {
                    "id": "M20295",
                    "name": "Glucose Intolerance",
                    "asFound": "Prediabetes",
                    "relevance": "HIGH"
                },
                {
                    "id": "M7115",
                    "name": "Diabetes Mellitus",
                    "relevance": "LOW"
                },
                {
                    "id": "M11639",
                    "name": "Metabolic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M25403",
                    "name": "Glucose Metabolism Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M7862",
                    "name": "Endocrine System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M9994",
                    "name": "Hyperglycemia",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC18",
                    "name": "Nutritional and Metabolic Diseases"
                },
                {
                    "abbrev": "BC19",
                    "name": "Gland and Hormone Related Diseases"
                }
            ]
        }
    },
    "hasResults": false
}